MedTrace Logo

OEA and LipiSperse Metabolic Study

NCT06840080 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 40

Last updated 2025-11-18

No results posted yet for this study

Summary

A placebo controlled, single blind, cross-over study evaluating the short-term effect of oleoylethanolamide (OEA) with LipiSperse supplementation on metabolic pathways in healthy participants.

Conditions

  • Healthy Volunteers - Male and Female
  • Pharmacokinetic Study in Healthy Volunteers

Interventions

DIETARY_SUPPLEMENT

125mg OEA with LipiSperse

Single dose of 2 capsules. 1 capsule contains 125mg of OEA and 13.9mg of LipiSperse, the other capsule is a placebo.

DIETARY_SUPPLEMENT

250mg OEA with LipiSperse

Single dose of 2 capsules. Each capsule contains 125mg of OEA and 13.9mg of LipiSperse.

OTHER

Placebo

Single dose of 2 capsules. Capsules contain the same excipients as the active arms, except for the OEA with LipiSperse in capsules that appear identical to the OEA with LipiSperse capsules

Sponsors & Collaborators

  • Gencor Pacific Limited

    collaborator UNKNOWN

  • RDC Clinical Pty Ltd

    lead INDUSTRY

Principal Investigators

  • Ramasamy Venkatesh · Gencor Pacific

Study Design

Allocation
NA
Purpose
OTHER
Masking
SINGLE
Model
CROSSOVER

Eligibility

Min Age
30 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2025-03-04
Primary Completion
2025-06-04
Completion
2025-06-04

Countries

  • Australia

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06840080 on ClinicalTrials.gov